Last reviewed · How we verify
Exubera
At a glance
| Generic name | Exubera |
|---|---|
| Sponsor | University of Pittsburgh |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus (PHASE3)
- Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents (PHASE3)
- This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus (PHASE4)
- Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
- A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus® (PHASE4)
- Follow-Up Study for Exubera
- A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma (PHASE3)
- Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |